(COO) The Cooper Companies - Ratings and Ratios
Contact Lenses, Fertility Devices, Intrauterine Devices, Surgical Instruments
Dividends
Currently no dividends paid| Risk via 10d forecast | |
|---|---|
| Volatility | 28.6% |
| Value at Risk 5%th | 41.8% |
| Relative Tail Risk | -11.17% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.74 |
| Alpha | -37.81 |
| CAGR/Max DD | -0.03 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.398 |
| Beta | 0.795 |
| Beta Downside | 0.665 |
| Drawdowns 3y | |
|---|---|
| Max DD | 42.17% |
| Mean DD | 14.33% |
| Median DD | 10.46% |
Description: COO The Cooper Companies October 30, 2025
The Cooper Companies (NASDAQ:COO) operates through two distinct businesses: CooperVision, which designs and sells a broad portfolio of contact lenses-including toric, multifocal, and spherical lenses-to address astigmatism, presbyopia, myopia, and other refractive errors across the Americas, Europe, the Middle East, Africa, and Asia-Pacific; and CooperSurgical, which focuses on family- and women-health products such as fertility consumables, intra-uterine contraceptive devices, cryostorage services, and genomic testing, sold to healthcare professionals and institutions worldwide.
In fiscal 2023, CooperVision generated roughly $3.0 billion in revenue, driven by a 12% year-over-year increase in myopia-control lens sales-a segment benefiting from rising myopia prevalence among children and young adults. CooperSurgical contributed about $1.2 billion, with fertility-related services growing at a compound annual growth rate (CAGR) of 9% since 2020, reflecting global demand for assisted-reproductive technologies and expanding cord-blood banking. Both segments are sensitive to macro-economic factors such as discretionary consumer spending, insurance reimbursement policies, and demographic trends (e.g., aging populations increasing demand for presbyopic lenses).
For a deeper quantitative assessment of COO’s valuation dynamics, you may find the ValueRay platform’s analyst tools useful for exploring forward-looking cash-flow models and peer-group benchmarks.
Piotroski VR‑10 (Strict, 0-10) 7.5
| Net Income (407.8m TTM) > 0 and > 6% of Revenue (6% = 242.7m TTM) |
| FCFTA 0.03 (>2.0%) and ΔFCFTA 1.77pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 27.87% (prev 25.16%; Δ 2.71pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.07 (>3.0%) and CFO 816.3m > Net Income 407.8m (YES >=105%, WARN >=100%) |
| Net Debt (2.35b) to EBITDA (1.09b) ratio: 2.16 <= 3.0 (WARN <= 3.5) |
| Current Ratio 2.12 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (200.6m) change vs 12m ago 0.0% (target <= -2.0% for YES) |
| Gross Margin 66.96% (prev 66.36%; Δ 0.60pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 33.05% (prev 31.42%; Δ 1.63pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 6.45 (EBITDA TTM 1.09b / Interest Expense TTM 111.7m) >= 6 (WARN >= 3) |
Altman Z'' 4.86
| (A) 0.09 = (Total Current Assets 2.14b - Total Current Liabilities 1.01b) / Total Assets 12.38b |
| (B) 0.61 = Retained Earnings (Balance) 7.56b / Total Assets 12.38b |
| (C) 0.06 = EBIT TTM 720.9m / Avg Total Assets 12.24b |
| (D) 1.79 = Book Value of Equity 7.19b / Total Liabilities 4.02b |
| Total Rating: 4.86 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 57.41
| 1. Piotroski 7.50pt |
| 2. FCF Yield 2.31% |
| 3. FCF Margin 10.18% |
| 4. Debt/Equity 0.30 |
| 5. Debt/Ebitda 2.16 |
| 6. ROIC - WACC (= -3.47)% |
| 7. RoE 4.97% |
| 8. Rev. Trend 97.02% |
| 9. EPS Trend -85.92% |
What is the price of COO shares?
Over the past week, the price has changed by -1.15%, over one month by +11.51%, over three months by +13.28% and over the past year by -26.62%.
Is COO a buy, sell or hold?
- Strong Buy: 9
- Buy: 2
- Hold: 8
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the COO price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 83 | 7.8% |
| Analysts Target Price | 83 | 7.8% |
| ValueRay Target Price | 79.1 | 2.7% |
COO Fundamental Data Overview December 03, 2025
P/E Trailing = 37.9461
P/E Forward = 17.9856
P/S = 3.8175
P/B = 1.8548
P/EG = 0.9781
Beta = 1.06
Revenue TTM = 4.05b USD
EBIT TTM = 720.9m USD
EBITDA TTM = 1.09b USD
Long Term Debt = 2.43b USD (from longTermDebt, last quarter)
Short Term Debt = 47.8m USD (from shortTermDebt, last quarter)
Debt = 2.48b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 2.35b USD (from netDebt column, last quarter)
Enterprise Value = 17.80b USD (15.44b + Debt 2.48b - CCE 124.9m)
Interest Coverage Ratio = 6.45 (Ebit TTM 720.9m / Interest Expense TTM 111.7m)
FCF Yield = 2.31% (FCF TTM 411.9m / Enterprise Value 17.80b)
FCF Margin = 10.18% (FCF TTM 411.9m / Revenue TTM 4.05b)
Net Margin = 10.08% (Net Income TTM 407.8m / Revenue TTM 4.05b)
Gross Margin = 66.96% ((Revenue TTM 4.05b - Cost of Revenue TTM 1.34b) / Revenue TTM)
Gross Margin QoQ = 65.26% (prev 67.75%)
Tobins Q-Ratio = 1.44 (Enterprise Value 17.80b / Total Assets 12.38b)
Interest Expense / Debt = 1.02% (Interest Expense 25.4m / Debt 2.48b)
Taxrate = 35.29% (53.6m / 151.9m)
NOPAT = 466.5m (EBIT 720.9m * (1 - 35.29%))
Current Ratio = 2.12 (Total Current Assets 2.14b / Total Current Liabilities 1.01b)
Debt / Equity = 0.30 (Debt 2.48b / totalStockholderEquity, last quarter 8.35b)
Debt / EBITDA = 2.16 (Net Debt 2.35b / EBITDA 1.09b)
Debt / FCF = 5.71 (Net Debt 2.35b / FCF TTM 411.9m)
Total Stockholder Equity = 8.21b (last 4 quarters mean from totalStockholderEquity)
RoA = 3.29% (Net Income 407.8m / Total Assets 12.38b)
RoE = 4.97% (Net Income TTM 407.8m / Total Stockholder Equity 8.21b)
RoCE = 6.77% (EBIT 720.9m / Capital Employed (Equity 8.21b + L.T.Debt 2.43b))
RoIC = 4.34% (NOPAT 466.5m / Invested Capital 10.76b)
WACC = 7.80% (E(15.44b)/V(17.92b) * Re(8.95%) + D(2.48b)/V(17.92b) * Rd(1.02%) * (1-Tc(0.35)))
Discount Rate = 8.95% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 33.33 | Cagr: 0.25%
[DCF Debug] Terminal Value 72.27% ; FCFE base≈322.8m ; Y1≈276.2m ; Y5≈214.6m
Fair Price DCF = 16.84 (DCF Value 3.35b / Shares Outstanding 198.8m; 5y FCF grow -17.55% → 3.0% )
EPS Correlation: -85.92 | EPS CAGR: -53.62% | SUE: -4.0 | # QB: 0
Revenue Correlation: 97.02 | Revenue CAGR: 9.32% | SUE: -0.23 | # QB: 0
EPS next Quarter (2026-01-31): EPS=1.00 | Chg30d=-0.002 | Revisions Net=+2 | Analysts=12
EPS next Year (2026-10-31): EPS=4.40 | Chg30d=-0.005 | Revisions Net=+1 | Growth EPS=+7.4% | Growth Revenue=+5.7%
Additional Sources for COO Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle